Enliven is developing highly selective tyrosine kinase inhibitors intended to reduce side effects and improve tolerability versus existing therapies. Its most advanced candidate, ELVN-001, targets BCR-ABL for chronic myeloid leukemia and is in a Phase 1 trial with preliminary data expected by the end of 2023. A second lead, ELVN-002, targets HER2 mutants for second-line HER2-mutant non-small cell lung cancer, with an investigational new drug filing planned later this quarter. The company plans to nominate a third product candidate in the first half of next year from multiple discovery-stage programs, including a CNS‑penetrant program. Enliven was founded in 2019 and has previously raised more than $140 million, including an $85 million Series B last December. Concurrent transactions will boost the company’s cash runway and support clinical development through early 2026. Enliven Therapeutics is a precision oncology company based in Boulder, Colorado, focused on the discovery and development of next-generation precision oncology therapeutics. The company combines clinically validated biological targets with industry-leading medicinal chemistry to design best-in-class and first-in-class therapies. Its pipeline targets cancers currently treated with suboptimal drugs, including both blood cancers and solid tumors, with an emphasis on improving tolerability, combinability, and resistance profiles. Enliven highlights rapid synthesis of diverse, drug-like compound libraries and applying unique insights to validated biology to accelerate development. The company launched from stealth after its July 2019 founding and emphasizes a leadership team of industry chemists, biologists, and top-tier advisors. Enliven has announced $55M raised across seed and Series A financings to advance its lead program and pipeline.

Total raised

$220M

Funding rounds

2

Latest round

Equity

Latest activity

Oct 2022